Serum Gal-3 levels are modulated by a range of clinical factors that contribute to the pathogenesis of various conditions, including metabolic disorders of carbohydrate and lipid metabolism, which play a key role in the progression of diabetes and colorectal cancer. Here, LGALS3 is linked to metabolic disease.